Bridge Biotherapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Bridge Biotherapeutics has a total shareholder equity of ₩19.7B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩32.7B and ₩13.0B respectively.
Key information
0%
Debt to equity ratio
₩0
Debt
| Interest coverage ratio | n/a |
| Cash | ₩20.18b |
| Equity | ₩19.72b |
| Total liabilities | ₩12.96b |
| Total assets | ₩32.68b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A288330's short term assets (₩21.7B) exceed its short term liabilities (₩10.4B).
Long Term Liabilities: A288330's short term assets (₩21.7B) exceed its long term liabilities (₩2.6B).
Debt to Equity History and Analysis
Debt Level: A288330 is debt free.
Reducing Debt: A288330 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A288330 has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: A288330 is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.